Innovative AI Trial Identifies Men Who Can Most Benefit From Prostate Cancer Medication

A team of researchers from the US, UK, and Switzerland have developed an artificial intelligence tool that can predict which men with prostate cancer will benefit from a medication called abiraterone. This medication has already improved the outlook for hundreds of thousands of men with advanced prostate cancer, and has been described as a potential “gamechanger”. However, some countries have hesitated to offer the medication to men with non-spread prostate cancer, due to concerns about its side effects and cost. The AI tool identifies the 25% of men who are most likely to benefit from abiraterone, allowing healthcare systems to offer the treatment to those who need it most and spare others from unnecessary treatment. The AI tool is being presented at the American Society of Clinical Oncology annual meeting and was developed by a team led by Nick James and Gert Attard. James argues that the AI tool could lead to NHS England reviewing its decision not to fund abiraterone for certain cases of prostate cancer. Prostate Cancer UK has also expressed support for making the treatment available to those who would most benefit.

Source: https://www.theguardian.com/society/2025/may/30/new-ai-test-can-predict-which-men-will-benefit-from-prostate-cancer-drug